14-15 NOVEMBER 2024

Portfolio Events

Evidence-based management of PPID and EMS

14 Nov 2024
RVC Equine Theatre 2
Endocrinology , Equine

Pituitary pars intermedia dysfunction (PPID) and equine metabolic syndrome (EMS) are two common equine endocrine disorders. Whilst the only drug that is currently licensed for the treatment of PPID in horses in the UK is pergolide, there are many questions that first opinion practitioners have relating to the management of this disease. The British Equine Veterinary Association (BEVA) primary care guidelines for the diagnosis and management of PPID were recently developed and will be discussed alongside the recently updated guidelines that are produced by the Equine Endocrinology Group (EEG) for this condition. Whilst diet and exercise designed to improve insulin sensitivity in animals with EMS are the main way that this condition is managed, there is increasing use of pharmacologic agents which aim to improve insulin sensitivity and consequently decrease the associated laminitis risk. The EEG guidelines for the diagnosis and management of EMS will be updated in 2024 and these will be discussed alongside the published evidence relating to the effectiveness of sodium glucose like transporter 2 (SGLT2) inhibitors.

Nicola Menzies-Gow, Professor of Equine Medicine - Royal Veterinary College

Education Partner

Platinum Sponsor

Gold Sponsor

Silver Sponsor

Media Sponsors

Be the leader of your pack

Be the first to hear the latest news, programme updates and exclusive industry releases.



Global Portfolio

BVA Live

12-13 June 2025

Deutsche Vet

16-17 May 2025

Singapore Vet

25-26 October 2024

Wild West Vet

16-19 October 2024

New York Vet

7-8 November 2024